Search - Leibniz Institute for Prevention Research and Epidemiology

391. [BIPS Project] PAS-study for alemtuzumab

URL: /en/research/projects/detail-view.html?projID=943&cHash=1349154bbd11f321c29994b2f766c31a
Date: 21-06-21

Alemtuzumab (LEMTRADA®), a highly efficacious disease modifying therapy (HE-DMT), is a monoclonal antibody indicated for the treatment of relapsing remitting multiple sclerosis (RRMS) in patients…

392. [BIPS Project] PAS-study for Brodalumab

URL: /en/research/projects/detail-view.html?projID=850&cHash=ca3027fc09de94936039549eef3d157e
Date: 01-10-19

"The Brodalumab assessment of hazards: A multinational safety study in electronic healthcare databases" Brodalumab (Kyntheum®) is a new monoclonal antibody for the treatment of moderate to severe…

393. [BIPS Project] PAS-study for eliglustat

URL: /en/research/projects/detail-view.html?projID=918&cHash=d876d3358dfbd42e2702cd0b2b6dc02e
Date: 30-06-21

Drug utilisation study of eliglustat for the treatment of Gaucher disease type 1 in Europe using electronic healthcare records Gaucher disease (GD) is a rare genetic disorder from the group of…

394. [BIPS Project] PAS-study for Entresto® (sacubitril/valsartan)

URL: /en/research/projects/detail-view.html?projID=802&cHash=8dbc9f677411b8e8f05616aac3f934c1
Date: 01-01-19

Angiotensin II antagonists (e.g. valsartan, lorsartan) are substances that lower blood pressure and cause vasodilation by modulating the renin-angiotensin system. Besides hypertension, some…

395. [BIPS Project] PAS-study for galcanezumab

URL: /en/research/projects/detail-view.html?projID=827&cHash=69f47eb761baaa0a1cab27c240e33036
Date: 01-03-19

Galcanezumab is a humanised monoclonal antibody against human calcitonin gene-related peptide and is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month…

396. [BIPS Project] PAS-study for Nocdurna® (desmopressin)

URL: /en/research/projects/detail-view.html?projID=917&cHash=f3708b280935a2f6fdb046a4bcf0808f
Date: 17-11-20

Post-authorisation safety study of nocdurna for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria: A multi-country cohort study using secondary data Nocdurna…

397. [BIPS Project] PAS-study for romosozumab

URL: /en/research/projects/detail-view.html?projID=911&cHash=0e924c8617af91ae44b78e9e81da7183
Date: 01-10-20

European non-interventional post-authorization safety study related to romosozumab Osteoporosis is a disease of the skeletal system that is associated with bone loss and changes in bone…

398. [BIPS Project] PAS-study for solriamfetol

URL: /en/research/projects/detail-view.html?projID=939&cHash=1c6fc18afaf3d549b79439bd5e94158a
Date: 15-06-22

PASS to evaluate cardiovascular events in adult patients with obstructive sleep apnoe (OSA) treated with solriamfetol Obstructive sleep apnea (OSA) is characterized by sleep fragmentation due to…

399. [BIPS Project] PAS-study for tralokinumab

URL: /en/research/projects/detail-view.html?projID=1040&cHash=61d281ea60f3f02b443b69dfb3b9577a
Date: 01-01-23

PAS-study of tralokinumab use in pregnancy Tralokinumab is a biological agent developed for the treatment of moderate to severe atopic dermatitis (AD) and is administered by subcutaneous…

400. [BIPS Project] PASS-study for upadacitinib

URL: /en/research/projects/detail-view.html?projID=1058&cHash=7c786a506c59206d88343acad19a145c
Date: 15-02-23

Upadacitinib (Rinvoq®) is a so-called Januskinase (JAK)-inhibitor which is approved for the treatment of chronic rheumatic diseases such as ulcerative colitis, rheumatic arthritis and atopic…